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Development of Quantitative Molecular Clinical End
Points for siRNA Clinical Trials
Robyn P. Hickerson1,7, Sancy A. Leachman2,7, Lana N. Pho2, Emilio Gonzalez-Gonzalez3,
Frances J.D. Smith4, W.H. Irwin McLean4, Christopher H. Contag3, Devin Leake5, Leonard M. Milstone6
and Roger L. Kaspar1,3
RNA interference (RNAi) is an evolutionarily conserved mechanism that results in specific gene inhibition at the
mRNA level. The discovery that short interfering RNAs (siRNAs) are selective, potent, and can largely avoid
immune surveillance has resulted in keen interest to develop these inhibitors as therapeutics. A single
nucleotide-specific siRNA (K6a_513a.12, also known as TD101) was recently evaluated in a phase 1b clinical trial
for the rare skin disorder, pachyonychia congenita (PC). To develop a clinical trial molecular end point for this
type of trial, methods were developed to: (1) isolate total RNA containing amplifiable mRNA from human skin
and callus material; (2) quantitatively distinguish the single-nucleotide mutant mRNA from wild-type K6a mRNA
in both patient-derived keratinocytes and patient callus; and (3) demonstrate that repeated siRNA treatment
results in sustained inhibition of mutant K6a mRNA in patient-derived keratinocyte cultures. These methods
allow noninvasive sampling and monitoring of gene expression from patient-collected shavings and may be
useful in evaluating the effectiveness of RNAi-based therapeutics, including inhibitors that specifically target
single-nucleotide mutations.
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INTRODUCTION
Pachyonychia congenita (PC) is a rare autosomal dominant
genodermatosis characterized by thickened nails, leukoker-
atosis, and painful keratoderma with blistering primarily on
the soles of the feet, which often necessitates ambulatory
aids (Leachman et al., 2005; Smith et al., 2006). Detailed
clinical data from a large PC case series will be published
elsewhere (Eliason et al.). Mutations in at least four keratin
(KRT) genes, including KRT6A, KRT6B, KRT16, and KRT17,
are responsible for the observed symptoms (see Wilson
et al., 2011). These mutations, which often include single-
nucleotide (nt) substitutions, cluster in the boundary motifs at
the ends of the keratin rod domain. These motifs
are associated with protein–protein interactions and
disrupt proper intermediate filament formation (Letai et al.,
1993; Smith, 2003; Lane and McLean, 2004; Smith et al.,
2005). The discovery of RNA interference (RNAi) and the
ability of short interfering RNAs (siRNAs) to selectively
and potently block expression of specific mRNAs in a
user-defined manner have opened up a new therapeutic
field. A few siRNAs have now entered clinical trials for
diseases including age-related macular degeneration and
melanoma, as well as a number of viruses, with others
in preclinical development (Dykxhoorn and Lieberman, 2006;
de Fougerolles et al., 2007; Kim and Rossi, 2007; Haussecker,
2008; Nguyen et al., 2008; Novobrantseva et al., 2008;
Castanotto and Rossi, 2009; Whitehead et al., 2009; Davis
et al., 2010; DeVincenzo et al., 2010).
Gene-specific siRNAs aimed at the most commonly
mutated keratin in PC, K6a, have been reported (Smith
et al., 2008). Moreover, potent siRNAs with single
nt specificity for a K6a mutation have been identified
(Hickerson et al., 2008a). The K6a_513a.12 siRNA phosphate
buffered saline-formulated good manufacturing practice
quality inhibitor is known as TD101), which specifically
targets the K6a p.Asn171Lys single nt mutation (Hickerson
et al., 2008a), has been evaluated for safety in a phase 1b
clinical trial for treatment of PC by repeated intradermal
injections (Leachman et al., 2010). PC is an ideal disorder
for evaluating the effectiveness of siRNA technology in
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clinical trials because: (1) no effective treatment exists
that addresses the underlying cause of PC (Leachman
et al., 2005, 2008); (2) the most problematic symptoms
are localized on or near the pressure points of the feet and are
readily accessible (Leachman et al., 2005); (3) the genetic
mutations are known and potent and specific siRNAs have
been developed (Smith, 2003; Smith et al., 2005; Hickerson
et al., 2008a); and (4) a central recruitment and dedicated
international patient registry has been developed and is
actively maintained by the non-profit PC patient support
organization, PC Project (see www.pachyonychia.org).
There are multiple ways in which treatment outcomes for
skin disorders, including PC, can be monitored and
measured, such as clinical assessment and subjective patient
responses, including the validated Dermatology Life Quality
Index (Finlay and Khan, 1994; Lewis and Finlay, 2004; see
also www.dermatology.org.uk). However, the ability to
quantitatively and efficiently measure whether a mutant
mRNA is inhibited in vivo would be beneficial in objectively
evaluating the effectiveness of the proposed treatment (e.g.,
siRNA). One way to measure the effectiveness of a mutation-
specific siRNA in a clinical trial would be to use quantitative
reverse transcription-PCR (QRT-PCR) to monitor the absolute
amount of target or alternatively the ratio of mutant to wild-
type K6a mRNAs present in tissue samples. To this end, a
method to isolate amplifiable mRNA from PC patient callus
shavings coupled with a QRT-PCR assay that quantitatively
discriminates mutant p.Asn171Lys from wild-type K6a is
reported in this study. The utility of this QRT-PCR approach
was demonstrated by showing specific knockdown of mutant
K6a mRNA following repeated siRNA treatment of patient-
derived keratinocytes.
RESULTS
Isolation of amplifiable RNA from patient plantar calluses
Isolation of intact RNA from human skin biopsies, but not
from noninvasive human skin callus shavings, has been
previously reported (Trost et al., 2007). In this study we
present a method to isolate RNA, not only from skin, but also
from patient skin callus. Various RNA isolation procedures
were compared using both shavings (large callus pieces
removed with a razor) and pumiced material (smaller
extractions from debridement with a pumice stone; data not
shown). The most reliable and reproducible procedure
involved collection of pumiced samples in RNALater
(Applied Biosystems, Foster City, CA), the mechanical
disruption of the tissue in a ‘‘bead-beater’’-type homogenizer
followed by isolation of total RNA (Supplementary Figure S1
online). It should be noted that the majority of the RNA
isolated from certain patient samples appear to be of bacterial
origin (Supplementary Figure S1c online).
Development and validation of allele-specific QRT-PCR
The QRT-PCR strategy was designed to allow single
nt discrimination of mutant and wild-type K6a mRNAs
(Figure 1). Primers were designed to flank the K6a
p.Asn171Lys mutation site in positions exhibiting the greatest
divergence from other highly related type II keratins. The
wild-type and mutant-specific probes were designed to
discriminate the K6a single nt change at position 513 and
to avoid genomic DNA amplification by flanking an intron.
In order to determine the ability of the QRT-PCR assay to
discriminate between mutant and wild-type K6a targets, total
RNA from cell lines that contain both K6a p.Asn171Lys
mutant and wild-type alleles (heterozygous PC-10 keratinocytes,
K6a   CTGACTCCCCTCAACCTGCAAATCGATCCCACCATCCAGCGGGTGCGGGCTGAGGAGCGT
K6b   CTGACTCCCCTCAACCTGCAAATTGACCCCGCCATCCAGCGGGTGCGGGCCGAGGAGCGT
K6c   CTGACTCCCCTCAACCTGCAAATTGACCCCGCCATCCAGCGGGTGCGGGCCGAGGAGCGT
K75   CTGACTCCTCTTCACCTGCAAATCGACCCCACCATCCAGCGGGTGCGGGCCGAGGAGCGC
K5    CTGACTCCCCTCAACCTGCAAATCGACCCCAGCATCCAGAGGGTGAGGACCGAGGAGCGC
K8    CTGAGCCCCCTTGTCCTGGAGGTGGACCCCAACATCCAGGCCGTGCGCACCCAGGAGAAG
K6a   GAACAGATCAAGACCCTCAACAACAAGTTTGCCTCCTTCATCGACAAGGTGCGGTTCCTG
K6b   GAGCAGATCAAGACCCTCAACAACAAGTTTGCCTCCTTCATCGACAAGGTGCGGTTCCTA
K6c   GAGCAGATCAAGACCCTCAACAACAAGTTTGCCTCCTTCATCGACAAGGTGCGGTTCCTA
K75   GAGCAGATCAAGACCCTCAACAATAAGTTCGCCTCCTTCATCGACAAGGTGAGGTTCTTG
K5    GAGCAGATCAAGACCCTCAACAATAAGTTTGCCTCCTTCATCGACAAGGTGCGGTTCCTG
K8    GAGCAGATCAAGACCCTCAACAACAAGTTTGCCTCCTTCATAGACAAGGTACGGTTCCTG
K6a   GAGCAGCAGAACAAGGTTCTGGAAACAAAGTGGACCCTGCTGCAGGAGCAGGGCACCAAG
K6b   GAGCAGCAGAACAAGGTTCTGGACACCAAGTGGACCCTGCTGCAGGAGCAGGGCACCAAG
K6c   GAGCAGCAGAACAAGGTTCTGGACACCAAGTGGACCCTGCTGCAGGAGCAGGGCACCAAG
K75   GAGCAGCAGAACAAGGTCCTGGAGACCAAGTGGGCCCTCCTGCAGGAGCAGGGCTCCAGG
K5    GAGCAGCAGAACAAGGTTCTGGACACCAAGTGGACCCTGCTGCAGGAGCAGGGCACCAAG
K8    GAGCAGCAGAACAAGATGCTGGAGACCAAGTGGAGCCTCCTGCAGCAGCAGAAGAC---G
Forward primer
Reverse primer
Probe
*
Figure 1. Design of quantitative reverse transcription-PCR (QRT-PCR) assays to allow K6a allelic discrimination. A sequence alignment of K6a, K6b,
K6c, K75, K5, and K8 complementary DNAs (cDNAs) is shown. Primers were designed to hybridize to K6a in regions that are distinct from the homologous
K6b and other related keratins and to flank a 1 kb intron (location noted with an asterisk). Wild-type- and mutant-specific probes were designed to anneal
such that the single-nucleotide (nt) difference at position 513 (designated with arrow) was near the middle of the hybridized region.
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immortalized keratinocytes derived from a PC patient with
the K6a p.Asn171Lys mutation) or homozygous wild-type
K6a alleles (HaCaT cell line) was analyzed. As expected,
approximately equal Ct values for wild-type and mutant K6a
were obtained from PC-10 cells, when probes were used
together or separately. HaCaT cells do not express
p.Asn171Lys mutant K6a mRNA; however, QRT-PCR analy-
sis of HaCaT total RNA with each probe separately
unexpectedly resulted in signal for both the wild type and
mutant. When both probes were used together, no mutant
K6a was detected, indicating that quantitative discrimination
of mutant and wild-type K6a mRNAs is achievable only if
both the wild-type and p.Asn171Lys mutant probes are
simultaneously present during the amplification reaction
(Table 1). Similar results were obtained using mutant and
wild-type plasmid DNA (data not shown).
To further investigate the robustness and accuracy of the
assay, known amounts of in vitro-transcribed mutant and
wild-type K6a mRNAs were measured by QRT-PCR in a
complex environment (Figure 2). Total RNA, isolated from
PC-2 cells (immortalized keratinocytes derived from a PC
patient with an irrelevant K16 p.Asn125Asp mutation) or
HaCaT cells, was ‘‘spiked’’ with in vitro-transcribed K6a
p.Asn171Lys mutant mRNA. Neither PC-2 nor HaCaT cells
express p.Asn171Lys mutant K6a mRNA; however, both cell
lines express wild-type K6a. 293FT cells, which do not
express K6a (see Supplementary Figure S2 online), were used
as a non-keratinocyte control. A constant amount of in vitro-
transcribed wild-type K6a mRNA (empirically determined to
generate Ct values similar to those observed from RNA
isolated from HaCaT and PC-2 cells) was added to total RNA
isolated from 293FT cells. To mimic the expected results of
siRNA treatment, decreasing amounts of p.Asn171Lys mutant
mRNA were added to each total RNA sample. The results
obtained in the background of homologous keratin mRNAs
(i.e., RNA isolated from PC-2 or HaCaT cells, which express
K5 and K6b among other keratins) show the same trend as in
the non-keratinocyte background (i.e., RNA from 293FT
cells, which express neither K5 nor K6b). These results
indicate that even in the presence of homologous keratins,
the amount of mutant K6a detected by QRT-PCR is directly
and linearly dependent on the amount present, indicating
that this assay can quantitatively distinguish mutant and
wild-type K6a mRNAs.
Patient-derived keratinocytes and calluses express equal
amounts of mutant and wild-type mRNAs
In order to determine the absolute K6a wild-type and
p.Asn171Lys mutant mRNA copy numbers in keratinocytes
and callus samples, standard curves were generated (Figure 3)
in which known amounts of in vitro-transcribed mutant
or wild-type K6a mRNAs were plotted against Ct values
generated by QRT-PCR. Based on these curves, absolute
amounts of wild-type and mutant K6a mRNAs were
determined in HaCaT cells and PC-10 cells, as well as
patient and control callus samples. Notably, the PC-10 cells
contain approximately equal amounts of K6a wild-type (820
molecules per cell) and mutant (1,100 molecules per cell)
mRNAs. Slightly lower levels of K6a wild-type mRNAs were
found in the human HaCaT keratinocyte line (490 molecules
per cell) and, as expected, no mutant K6a mRNA was
detected. RNA isolated from callus samples of three patients
harboring the p.Asn171Lys mutation contained equal levels
of mutant and wild-type K6a mRNAs (data shown only for
patient IPCRR no. 10), whereas no mutant K6a mRNA was
detected in callus samples from a non-PC volunteer or ten PC
patients with mutations in K6a (other than K6a p.Asn171Lys),
K6b, K16, or K17 (e.g., Callus no. 2 from IPCRR Patient no. 2
harbors the K16 p.Asn125Asp mutation).
siRNA treatment results in sustained inhibition of mutant K6a
To investigate the potential utility of this assay for monitoring
the effectiveness of siRNA treatment in which the
Table 1. Single-nucleotide discrimination of wild-type
and mutant targets is observed only with mutant and
wild-type probes in the same qPCR reaction
Probes separate Probes together
Cell line Ct (WT) Ct (MUT) Ct (WT) Ct (MUT)
PC-10 20.3±0.1 20.1±0.1 20.6±0.1 20.4±0.1
HaCaT 20.8±0.1 23.7±0.3 21.0±0.1 None detected
Abbreviations: Ct, PCR cycle threshold; PC-10, pachyonychia congentia-10;
WT, wild-type; qPCR, quantitative PCR.
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Figure 2. Quantitative reverse transcription-PCR (QRT-PCR) assay
discriminates between p.Asn171Lys and wild-type K6a regardless of keratin
background. Decreasing amounts of p.Asn171Lys mutant in vitro-transcribed
mRNA were added to total RNA isolated from the indicated cell lines
(mimicking the expected result of small interfering RNA (siRNA) treatment) to
demonstrate the specificity and sensitivity of the QRT-PCR assay (a constant
amount of in vitro-transcribed wild-type K6a mRNA was added to total RNA
from 293FT cells). The RNA samples were subjected to QRT-PCR using the
combined K6a wild-type/p.Asn171Lys assay (glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as the reference gene). The amount of mutant K6a
detected under the indicated conditions was normalized to the 100% mutant
data point for each cell line. The data are reported as the ratio of normalized
p.Asn171Lys to normalized wild-type mRNA levels. Error bars represent
standard error.
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p.Asn171Lys mutation is targeted, PC-10 cells were treated
with mutant-specific siRNA (K6a_513a.12). Following a
24-hour incubation, total RNA was isolated and analyzed
by QRT-PCR. Figure 4a shows that K6a_513a.12 siRNA
potently and specifically inhibits mutant K6a mRNA levels
(98% reduction), with no effect on K6a wild-type mRNA
levels. Furthermore, little or no effect was observed on other
related keratin mRNAs, including K6b, or on the unrelated
EGFR. The modest inhibition observed for K16 is repro-
ducible and has been seen in other laboratories (Wong and
Coulombe, 2003; FJD Smith, unpublished data) and may
result from feedback inhibition following downregulation of
its binding partner K6a. These data indicate that p.Asn171Lys
mutant-specific siRNA potently targets mutant K6a mRNA
with little or no nonspecific effects on related keratin gene
expression in patient-derived keratinocytes, and that the
effectiveness of the siRNAs can be readily and quantitatively
measured by QRT-PCR.
As repeated siRNA administration will be necessary in
treating dominant genetic diseases, PC-10 cells were
repeatedly treated (every 4 days) with the mutant-specific
siRNA (K6a_513a.12) and control siRNA (targets enhanced
green fluorescent protein (EGFP), which is not present
in these cells). Total RNA was isolated and analyzed by
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Figure 3. Quantitative determination of p.Asn171Lys mutant and wild-type
K6a mRNA amounts in callus samples obtained from pachyonychia
congenita (PC) patients. (a) A standard curve was generated by reverse
transcription of known quantities of in vitro-transcribed wild-type and mutant
p.Asn171Lys K6a mRNAs. Decreasing amounts of reverse-transcribed
material were analyzed by quantitative PCR (QPCR). Error bars represent
standard error (SE). (b) Determination of absolute amounts of wild-type and
mutant K6a in callus and cultured keratinocytes. Ct values obtained from PC
patient callus complementary DNA (cDNA) or 1 ng cDNA from PC-10 and
HaCaT cells are reported (SE are reported in parentheses). Molecules per mg
of callus sample or tissue culture cells and molecules per tissue culture cell
are also reported using the standard curve generated in a.
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Figure 4. Single-nucleotide (nt)-specific small interfering RNA (siRNA)
reduces mutant K6a levels in the patient cell line. (a) PC-10 cells were
treated with K6a_513a.12 (targets p.Asn171Lys mutant K6a mRNA) or control
siRNA (targets enhanced green fluorescent protein (EGFP)) at the indicated
time points (arrows). Following a 24-hour incubation, RNA was isolated
and subjected to quantitative reverse transcription-PCR (QRT-PCR) analysis
using the indicated primer/probe assays (glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as the reference gene). All data generated
were normalized to EGFP siRNA-treated cells. (b) PC-10 cells were repeatedly
treated (labeled ‘‘R’’ in the figure insert) with K6a_513a.12 or control
EGFP siRNA at 0, 96, 192, and 288 hours. At the indicated time points,
samples were processed as described in a. Normalized mutant K6a expression
relative to wild-type (WT) K6a expression is plotted for each sample showing
specific and sustained knockdown. Error bars represent standard error.
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QRT-PCR every 24 hours. The levels of mutant mRNA
decreased relative to wild-type within a few hours following
treatment with the mutant-specific siRNA, whereas there was
no change when treated with the control siRNA (Figure 4b).
Determination of mRNA cleavage site
To demonstrate that the observed mutant K6a knockdown
was due to siRNA-mediated cleavage, K6a mRNA cleavage
products from total RNA isolated from K6a_513a.12 siRNA-
treated PC-10 cells were characterized using a modified 50
RACE (rapid amplification of complementary DNA (cDNA)
ends) technique (Soutschek et al., 2004). As shown in
Supplementary Figure S3 online, the cleavage site is between
residues 10 and 11 of the siRNA antisense strand (between
positions 514 and 515 in the K6a cDNA), consistent with
previously published RISC (RNA-induced silencing complex)-
mediated cleavage data (Elbashir et al., 2001).
DISCUSSION
A clear demonstration of the clinical efficacy of therapeutic
siRNAs in PC patients should pave the way for treatment of
other dominant negative genodermatoses including epider-
molysis bullosa simplex, epidermolytic palmoplantar kerato-
derma, bullous congenital ichthyosiform erythroderma, and
many other dominant skin disorders (Lane and McLean,
2004). The single nt specificity of the siRNAs that we
(Hickerson et al., 2008a) and others (Brummelkamp et al.,
2002; Ding et al., 2003; Miller et al., 2003; Dykxhoorn
et al., 2006; Hengge, 2006; Schwarz et al., 2006; Klootwijk
et al., 2008; Pfister et al., 2009) have demonstrated suggests
that this approach may be useful, particularly for dominant
negative disorders, if efficient delivery can be achieved. The
ability to quickly identify appropriate siRNAs coupled with
the ability to assay their effectiveness using approaches, such
as the QRT-PCR protocol described in this study, may usher
in an era of individualized medicine. Offending dominant
genes could be identified (perhaps by gene array technology
or high-throughput sequencing), followed by design, pre-
paration, and selection of potent and mutation-specific
siRNAs that, following appropriate testing for safety and
efficacy, would be administered to patients. The effective-
ness of these inhibitors could be monitored through
subjective observation as well as using molecular end points
including QRT-PCR assays, such as the one described in
this study.
Quantitative molecular end points are of crucial impor-
tance for objectively evaluating the effectiveness of test
agents in clinical trials. In preparation for future clinical trials
in which PC patients will be treated with mutant-specific
siRNAs (e.g., K6a_513a.12 targeted to the K6a p.Asn171Lys
mutation; Leachman et al., 2008, 2010; Hickerson et al.,
2008a), a method to measure mutant versus wild-type mRNA
levels by QRT-PCR was developed.
In designing the QRT-PCR assay, we sought to satisfy the
National Clinical Laboratory criteria utilized by ARUP
Laboratories (http://www.clsi.org/Source/Custom/Currentdocs.
cfm?Section=Current_Versions_of_CLSI_Documents&CFID=
3081615&CFTOKEN=53505146) and the NYC Department
of Health (http://www.wadsworth.org/labcert/TestApproval/
submitguide.htm) for clinical QRT-PCR assays, namely:
confirmation of appropriate analytical specificity and sensitiv-
ity (Figure 2), minimal ‘‘between-run’’ and ‘‘within-run’’
variation (Supplementary Table S1 online), defined limits of
detection (Figure 3), and appropriate clinical sensitivity
(Supplementary Figure S4 online).
The single nt specificity of the QRT-PCR assay was
demonstrated by assaying total RNA from PC-10 cells that
contain equal amounts of wild-type and p.Asn171Lys mutant
K6a mRNA and from HaCaT keratinocytes that express only
wild-type K6a. As shown in Table 1, both probes must be
used simultaneously in order to achieve the expected result.
The wild-type probe was also able to discriminate mutant and
wild-type plasmid under all conditions tested. However, the
mutant probe was able to discriminate mutant and wild-type
plasmid only in the presence of the wild-type probe (data not
shown). The ability of the wild-type probe to differentiate
between mutant and wild-type targets may result from the
formation of a C:G base pair with the wild-type cDNA,
whereas hybridization of the mutant probe to the mutant
cDNA results in an A:T base pair. In addition to the increased
stability of the wild-type canonical base pair, the wild-type
probe mismatch with the mutant cDNA results in a sterically
bulky G:A mismatch as opposed to the more easily tolerated
C:T mismatch resulting from the mutant probe mismatch with
the wild-type cDNA. The unexpected observation that
complete discrimination was achieved only when both the
wild-type and mutant probes were used simultaneously
suggests that competition for the target is necessary to
achieve the desired single nt specificity.
The usefulness of the single nt-specific QRT-PCR assay is
dependent on the ability to extract sufficient amounts and
quality of RNA from patient samples (skin or callus) that can
be quantitatively analyzed. The specific and reproducible
amplification of a variety of keratin mRNAs (K6a, K6a
p.Asn171Lys, K6b, K5, K14, K16, and K17) and non-keratin
RNAs (18S rRNA; GAPDH (glyceraldehyde-3-phosphate
dehydrogenase), b-actin, and lamin A/C mRNAs) from RNA
extracted from PC patient callus samples suggests that
sufficiently intact mRNA can be isolated that can be
evaluated in a quantitative fashion (Supplementary Figure
S2 online). This work shows that QRT-PCR can be performed
on RNA isolated from patient shavings (obtained by
noninvasive means). To our knowledge, this is previously
unreported. It should be noted that amplifiable RNA can also
be obtained from skin by tape harvesting and mRNA
expression levels determined by DNA microarray or QRT-
PCR (Wong et al., 2004; Benson et al., 2006). In addition to the
ability to measure relative amounts of mRNAs in human tissue
and cell lines, wild-type and mutant K6a absolute mRNA copy
numbers in both patient callus samples and keratinocyte cell
lines (HaCaT and PC-10) were determined using the single
nt-specific QRT-PCR assay described in this study.
The mode of TD101 administration during the recently
completed TD101 Phase Ib clinical trial (Leachman et al.,
2010) was via intradermal injection (twice per week; Leachman
et al., 2010). Intradermal injection(s) of reporter-specific
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siRNA was previously shown to inhibit reporter gene
expression in mouse skin models (Wang et al., 2007; Smith
et al., 2008; Hickerson et al., 2008a, b; Gonzalez-Gonzalez
et al., 2009). Although no adverse events were noted, and
signs of efficacy were observed, intradermal injections were
determined to be unacceptable because of intolerable pain.
Therefore, alternative ‘‘patient-friendly’’ delivery methods
are currently under development. The ability to repeatedly
and reproducibly knock down mutant K6a mRNA levels
(with no effect on wild-type; see Figure 4b) with sequential
siRNA treatments in PC patient-derived keratinocytes
bodes well for repeated treatments in a clinical setting
if patient-friendly delivery technologies can be developed.
The demonstration that quantifiable mRNA can be isolated
from skin and skin callus and single nt differences between
K6a wild-type and p.Asn171Lys mutant mRNAs can be
discriminated by QRT-PCR suggests that these methods may
be useful for measurement of molecular end points in future
clinical trials.
MATERIALS AND METHODS
Plantar skin shavings and skin explants
Affected callused areas on the plantar surface of PC patients were
collected with institutional review board approval (Western IRB no.
1057496), and callused regions were obtained from a volunteer
control. The study was conducted according to the Declaration of
Helsinki Principles, and the participants gave written informed
consent. Each sample was collected during routine grooming by PC
participants and included the outer layers of the callus that would
normally be discarded. Shavings were immediately placed in
RNALater (Applied Biosystems) and stored at 4 1C. After 24 hours,
samples were transferred to 20 1C for no longer than 2 weeks, at
which time samples were transferred to 80 1C for long-term storage
until total RNA extraction was performed.
De-identified human skin (from abdominoplasty procedures) was
obtained with informed consent from a local surgeon and used
within 1–4 hours following surgical removal. Adipose tissue was
removed before RNA isolation.
RNA isolation
Total RNA was prepared using a FastPrep instrument (FastPrep-24,
FP24, from MP Biomedicals, Solon, OH) to mechanically lyse the
cells and the RNeasy Mini Kit (Qiagen, Valencia, CA) to isolate pure
RNA. Frozen callus samples (in RNALater) were thawed at 4 1C and
B30mg of sample was placed in a 2ml tube prefilled with 1.2 g
‘‘D’’ lysing matrix (MP Biomedicals). The skin explant tissue was
similarly processed. Qiazol (1ml; Qiagen) was added and the
samples were immediately processed in the FP24 homogenizer,
three times at a setting of 6.0m s–1 for 40 s with a 2-minute
incubation on ice between each round. To remove debris, samples
were centrifuged twice for 5minutes each at 12,000 g at 21 1C,
followed by addition of 200ml chloroform. Samples were vortexed,
incubated at 21 1C for 5minutes and then centrifuged at 12,000 g
for 15minutes at 4 1C. The aqueous layer was transferred to a clean
tube and an equal volume of 70% ethanol was added. The sample
was loaded on an RNeasy column provided with the RNeasy Mini
Kit, treated with DNase, and eluted with 30 ml RNase-free water as
described by the manufacturer.
Reverse transcription
RNA isolated from skin or plantar callus samples or tissue culture
cells was reverse transcribed using the Superscript III First Strand
Synthesis System (Invitrogen, Carlsbad, CA) following the manufac-
turer’s instructions. Briefly, 1–2 mg of total RNA isolated from skin
samples or tissue culture cells was incubated with random hexamer
primers (5 ng ml–1) and dNTPs (1mM) at 65 1C for 5minutes in a total
volume of 10 ml and then placed on ice for at least 1 minute. Owing
to bacterial contamination, it was not possible to quantify the
amount of RNA isolated from PC patient callus samples; therefore,
8ml of a total RNA sample (30 ml fromB30mg callus) was added to
the reverse transcription reaction. The reverse transcription reaction
was performed by addition of 1ml Superscript III reverse transcriptase
(200U ml–1) and 1ml RNase OUT (40U ml–1) in 1 buffer (20 ml final
volume) at 25 1C for 10minutes, followed by 50 1C for 30minutes.
The enzyme was heat denatured at 85 1C for 5minutes.
In vitro-transcribed RNA
K6a wild-type or p.Asn171Lys mutant mRNA was in vitro-
transcribed from 1.4 mg XhoI-linearized plasmid (pTD103 and
pTD104; Hickerson et al., 2008a) using the Ampliscribe T7-Flash
Transcription Kit (Epicentre Biotechnologies, Madison, WI). The
in vitro-transcribed RNA was purified using a G-50 gel filtration
column (Bio-Rad, Hercules, CA).
Reverse transcription of in vitro-transcribed RNA added to
total RNA
A fixed amount of in vitro-transcribed wild-type K6a RNA (0.1 ng)
and decreasing amounts of in vitro-transcribed mutant p.Asn171Lys
RNA (from 100% (i.e., 0.1 ng) to 0% of the wild-type K6a RNA
added) were added to 1 mg of total RNA from 293FT cells.
Decreasing amounts of in vitro-transcribed K6a mutant RNA
(0.1–0 ng) were added to 1mg of total RNA isolated from HaCaT or
PC-2 keratinocytes. Samples were reverse transcribed as described
above.
QRT-PCR
The K6a TaqMan assay (Applied Biosystems) consists of forward and
reverse primers (50-TCAACCTGCAAATCGATCCC-30 and 50-
AGGGTCCACTTTGTTTCCAGAA-30 respectively) and 6-FAM-la-
beled wild-type-specific and VIC-labeled mutant-specific TaqMan
MGB probes (50-AGACCCTCAACAACAAGT-30 and 50-AGACCCTC
AAAAACAAGT-30, respectively) (underline shows single nt change).
Inventoried TaqMan assays for K5 (Hs00361185_m1), K6b
(Hs00749101_s1), K14 (Hs00559328_m1), K16 (Hs00373910_g1),
K17 (Hs01588578_m1), EGF-R (Hs01076073_m1), 18S rRNA
(Hs99999901_s1), b-actin (Hs99999903_m1), GAPDH (Hs99999
905_m1), and lamin A/C (Hs00153462_m1) were purchased from
Applied Biosystems. A typical QPCR reaction was prepared as
follows: 1.25 ml 20 primer/probe mix, 6.25ml H2O, and 12.5 ml
2 master mix were combined such that the final primer and probe
concentrations were 200 and 120 nM, respectively. A total of 5 ml of
cDNA (0.2 ng ml–1 for samples prepared from skin samples or tissue
culture cells or the maximum possible concentration of cDNA
prepared from each callus sample) was then added to each well and
analyzed using the ABI standard 7500 procedure. The data were
analyzed using the Applied Biosystems Sequence Detection software
(version 1.4) and reported as the number of PCR cycles required to
1034 Journal of Investigative Dermatology (2011), Volume 131
RP Hickerson et al.
Quantification of Mutant Keratin mRNA
achieve a threshold fluorescence for a specific cDNA, defined as
the ‘‘Ct’’ value or as the relative quantitation using GAPDH as the
reference gene. All data points reported are the mean of three
replicate assays and error is reported as the standard error.
Preparation of immortalized keratinocyte cell lines
Skin biopsy specimens from previously genotyped patients were
collected with institutional review board approval (Western IRB no.
1057496) and were shipped overnight at 4 1C in culture medium.
Keratinocytes obtained from epidermal sheets from those biopsies
were initially grown on 3T3 feeder cells and then expanded in low
calcium medium, as described previously (Schwartz et al., 1992).
Second passage cells were transduced with high-titer supernatants
containing human papilloma virus (HPV) 16 E6/E7 genes in the
LXSN retroviral vector (Halbert et al., 1991). Cells were split twice a
week at a ratio of 1:3 for 3 weeks and then once a week at 1:10
thereafter. Immortalization was assumed after the tenth passage, the
time at which normal cells show distinct slowing of growth.
Keratinocyte lines (PC-10 and PC-2) for the experiments described
were used after the twelfth passage.
siRNA transfection
PC-10 immortalized keratinocytes were transfected with RNAiMAX
(Invitrogen) according to the manufacturer’s instructions for ‘‘reverse
transfection.’’ Mutant-specific (K6a_513a.12; Hickerson et al.,
2008a) and nonspecific control (SMARTselected EGFP-specific
siRNA; Thermo Fisher Scientific, Dharmacon Products, Lafayette,
CO; Wang et al., 2007) siRNAs were diluted in 25 ml optiMEM
medium in a well of a 24-well plate (15 nM final concentration after
addition of cells). A total of 1ml of RNAiMAX lipofectamine
(Invitrogen) was diluted in 25 ml of optiMEM medium and
immediately added to the nucleic acid solution and left for
10–15minutes at 21 1C. Trypsinized PC-10 cells (55,000 cells in
450ml) were then added to the well and gently mixed before
incubation. Cells were lysed with 1ml Qiazol, and RNA was isolated
using the RNeasy Mini Kit. The resulting RNA samples were
subjected to QRT-PCR as described above.
50 RACE analysis
Total RNA was isolated as described above from 500,000 PC-10
keratinocytes treated with 3 nM mutant-specific K6a_513a.12 siRNA
for 6 hours. mRNA was isolated with the Oligotex mRNA Mini Kit
(Qiagen) and subjected to a modified 50 RACE procedure as
described (Soutschek et al., 2004) using the K6a gene-specific
primer K6a-sp242 (50-GGGTGCTCAGATGGTATAGAG-30). The
resulting PCR product was ligated into the pCRII-TOPO vector and
confirmed by sequencing.
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